(Translation)

June 24, 2024

To Shareholders,

Company Name Renascience Inc.
Name of Representative: Koji Naito, President & CEO
(Code: 4889 TSE Growth)
For inquiries, please contact Administration Dept.

Announcement of Initiation of Multicenter Clinical Study on Disposable Ultrafine Endoscopes

The Company is pleased to announce a multicenter clinical study on the disposable ultrafine endoscope for the purpose of "developing a clinical guideline for diagnosis with this medical device".

Peritoneal dialysis is a treatment that allows home dialysis and has medical economic advantages. However, it must be discontinued after about five (5) years because the peritoneal membrane deteriorates over time and can cause serious complications. Currently, the only methods to check the condition of the peritoneum are laparotomy or laparoscopic observation, both of which are very burdensome for the patient. A peritoneal dialysis patient always has a tube inserted into the peritoneum to inject dialysate solution. In collaboration with Tohoku University and other universities, the Company has developed an ultrafine endoscope (disposable product with a diameter of approximately 1 mm) that can be inserted through this thin tube to noninvasively observe the intraperitoneal cavity.

In August 2022, the fiberscope, the main component of the endoscope, was filed for regulatory approval to the Pharmaceuticals and Medical Devices Agency (PMDA), and in December 2022, it was approved by the Ministry of Health, Labour and Welfare (MHLW). In September 2022, the Company concluded the collaboration agreement with HILEX Corporation and its subsidiary, HILEX Medical on the development of medical devices including the guide catheter, the auxiliary component of the endoscope. In May 2024, the Company entered into a license agreement with HI-LEX Medical. and plans to file a complete set of a guide catheter and fiberscope for regulatory approval in fiscal 2025.

In November 2022, the Board of Directors of the Japanese Society for Peritoneal Dialysis (JSPD) authorized to support and promote this medical device as a JSPD-supported research project, and in December 2023, the JSPD Scientific Committee approved to conduct clinical research on this medical device. A multicenter collaborative clinical study (60 cases) to establish a clinical guideline for diagnosis with this medical device has begun at the end of May 2024 and has been conducted at St. Luke's International Hospital, The Jikei University Hospital, The Jikei University Katsushika Medical Center, Juntendo University Hospital, Juntendo University Nerima Hospital, and The University of Tokyo Hospital.

Through this study, clinical data will be obtained for the development of the guidelines for commercialization.

There will be no impact on full-year results for the fiscal year ending March 31, 2025.

(*1) Fiberscope (disposable): The main body of a disposable ultrafine endoscope. The tip is about 1 mm in diameter and passes through a tube implanted in the abdomen.

(*2) Guide catheter (disposable): Used in combination with a fiberscope, the tip of the fiberscope can be moved freely. Although it is possible to observe the state of the peritoneum with the fiberscope alone, the guide catheter improves the operability of the endoscope.

End